Vinpocetine for people with Parkinson's on levodopa
Clinical Study to Evaluate Safety and Effectiveness of Vinpocetine in Patients With Parkinsonian Disease
PHASE2; PHASE3 · Tanta University · NCT07229664
This trial will test whether adding vinpocetine to levodopa/carbidopa helps improve motor symptoms in people aged 50 and older with Parkinson's disease.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 50 Years to 70 Years |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Tanta) |
| Trial ID | NCT07229664 on ClinicalTrials.gov |
What this trial studies
This randomized interventional Phase 2/3 trial enrolls patients aged 50 and older with Parkinson's disease who are already taking levodopa/carbidopa and gives vinpocetine as an add-on treatment compared with standard therapy. The protocol focuses on motor function and safety outcomes while excluding patients with atypical or secondary parkinsonism, prior stereotaxic surgery, cardiovascular disease, coagulation disorders, active malignancy, pregnancy or lactation, substance addiction, or known allergy to the study drugs. Patients taking anti-inflammatory drugs are also excluded to avoid confounding and bleeding risk. The trial is being conducted at Tanta University in Tanta, Egypt.
Who should consider this trial
Good fit: Ideal candidates are adults aged 50 or older with a clinical diagnosis of Parkinson's disease who are currently taking levodopa/carbidopa and who do not have the listed exclusion conditions.
Not a fit: Patients with atypical or secondary parkinsonism, prior stereotaxic surgery, active malignancy, cardiovascular or coagulation disorders, current pregnancy or lactation, active substance addiction, use of anti-inflammatory drugs, or known allergy to the study drugs are unlikely to be eligible or to receive benefit from this trial.
Why it matters
Potential benefit: If successful, adding vinpocetine to levodopa could modestly improve motor symptoms and daily functioning for people with Parkinson's disease.
How similar studies have performed: There is limited prior clinical trial evidence for vinpocetine in Parkinson's disease, so this approach is relatively novel and not yet proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age ≥ 50 years Both male and female will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa Exclusion Criteria: Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Cardiovascular disease patients Patients with coagulation disorders Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications
Where this trial is running
Tanta
- Tanta Unuversity — Tanta, Egypt (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Parkinson Disease